Insilico Medicine extended its dealmaking by signing a discovery collaboration with Takeda valued at up to $600 million in biobucks, including a $60 million upfront payment. Takeda will use Insilico’s Pharma.AI platform to identify drug candidates across multiple therapeutic areas. Insilico will lead AI-driven discovery, while Takeda will advance any selected assets through development. The structure highlights a recurring industry pattern: pharma is outsourcing early-stage candidate identification to AI platforms while retaining downstream development responsibility. The collaboration adds to a crowded market for compute- and model-led discovery partnerships, where differentiation increasingly depends on how effectively AI output translates into developable biology and clinical candidates.